NCR3 and breast carcinoma: We have already mentioned the multiple myeloma paper by Stikwoort et al. [36], but there are likewise many other examples of preclinical investigations, such as the work by Lin et al., who constructed a CAR containing the NK cell AR NKp30 (also called natural cytotoxicity receptor 3 or NCR3) targeting one of its ligands, namely B7-H6, expressed by anti-estrogen resistant breast cancer cells.